scFv-Transferrin Fusion Protein for Barrier-Penetrating Antibody Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis, with enzymatically or pH-sensitive linkers for controlled release within target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used, then effector functions and half-life are enhanced, but penetration across biological barriers is reduced
Solution Approach 1:
The antibody is segmented into functional components: the scFv fragment retains antigen-binding capability while the Fc region is removed or reduced. This segmentation allows the antibody to cross biological barriers more effectively while maintaining necessary binding functions through the variable regions alone.
Solution Approach 2:
Transferrin is used as an intermediary protein to facilitate the transport of the scFv across biological barriers. The scFv binds to transferrin, which then utilizes its receptor-mediated endocytosis pathway to deliver the scFv into cells, effectively overcoming the barrier penetration limitation of conventional antibodies.
2Length of moving object
If scFv is used, then penetration across biological barriers is improved, but effector functions are reduced
Solution Approach 1:
Transferrin serves as a mediator that compensates for the reduced effector functions of scFv. By binding to transferrin, the scFv gains enhanced cellular uptake through transferrin receptor-mediated endocytosis, effectively achieving both improved penetration and restored functional efficacy.
Solution Approach 2:
The scFv is merged with transferrin to create a fusion protein that combines the barrier-penetrating properties of scFv with the cellular uptake capabilities of transferrin. This merging restores effector functions by enabling the scFv to be delivered into cells where it can exert its therapeutic effect.
3Reliability
If conventional antibodies are used, then immune responses are triggered, but delivery to specific tissues is reduced
Solution Approach 1:
The scFv-transferrin fusion protein exhibits local quality by specifically targeting tissues that express transferrin receptors, such as the blood-brain barrier and certain cancer cells. This localized binding and internalization enables precise delivery to specific tissues while maintaining the ability to trigger immune responses where needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-transferrin fusion protein improves delivery and efficacy by enhancing penetration across barriers and ensuring targeted release within specific cells, reducing off-target effects and increasing therapeutic potency.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis
Implementation Method 2
enzymatically or pH-sensitive linkers for controlled release within target cells
Implementation Method 3
enzymatically or pH-sensitive linkers for controlled release within target cells
Data Source
AI summary
The efficacy and indication of prasinezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.